Inmed announces conclusion of patient enrollment in phase 2 clinical trial investigating inm-755 cannabinol cream for epidermolysis bullosa

Marks the first time a phase 2 trial has studied a cannabinol (cbn) formulation as a treatment option for any disease data expected to be released in early calendar q3 2023 vancouver, british columbia--(newsfile corp. - march 28, 2023) - inmed pharmaceuticals inc. (nasdaq: inm) ("inmed" or the "company"), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announced it has concluded enrollment of its phase 2 clinical trial using investigational drug inm-755 cannabinol ("cbn") cream for the treatment of patients with epidermolysis bullosa ("eb"), a rare genetic skin disease. the phase 2 study, called inm-755-201-eb, enrolled 19 patients.
INM Ratings Summary
INM Quant Ranking